Risedronate — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Osteoporosis

• Alendronate
• Ibandronate
• Raloxifene

Other medications in Musculoskeletal

• Acetaminophen
• Allopurinol
• Celecoxib
• Colchicine
• Diclofenac
• Febuxostat
• Indomethacin
• Meloxicam

About Risedronate

Risedronate is a vital medication prescribed to strengthen bones and combat conditions like osteoporosis. For many, managing chronic conditions can be costly, but with TheDrugClub, accessing essential treatments like risedronate doesn't have to break the bank. Our members enjoy significant savings, making bone health more affordable and accessible than ever before.

What Risedronate Treats

Risedronate is a powerful medication primarily used to prevent and treat osteoporosis. This condition causes bones to become weak and brittle, leading to an increased risk of fractures, especially in the hip, spine, and wrist. Risedronate is prescribed for postmenopausal women, men, and sometimes those on corticosteroid therapy who are at high risk of osteoporosis. It's also used to treat Paget's disease of bone, a condition where bone remodeling is

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Risedronate is approved for (FDA label)

Risedronate sodium tablets are a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis ( 1.1 ) Treatment to increase bone mass in men with osteoporosis ( 1.2 ) Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.3 ) Treatment of Paget’s disease ( 1.4 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. ( 1.5 ) 1.1 Postmenopausal Osteoporosis Risedronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women.

Source: Read the full FDA label on DailyMed. Label effective date: March 30, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Risedronate (FDA label)

5 mg: yellow, round, standard convex, film-coated, debossed with “TEVA” on one side of the tablet and “7390” on the other side. 30 mg: white, round, standard convex, film-coated, debossed with “TEVA” on one side of the tablet and “7391” on the other side. 35 mg: orange, round, standard convex, film-coated, debossed with “TEVA” on one side of the tablet and “7389” on the other side. Tablets: 5 mg, 30 mg, and 35 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: dddcd321-4d2e-4643-bf3c-7b752b33ba39. SPL document ID: 641c2a59-be2b-4246-8990-b7bf563012be. Label effective date: March 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Risedronate (FDA label)

The following clinically significant adverse drug reactions are described elsewhere in the labeling: Drug Products with the Same Active Ingredient [see Warnings and Precautions ( 5.1 )] Upper Gastrointestinal Adverse Reactions [see Warnings and Precautions ( 5.2 )] Mineral Metabolism [see Warnings and Precautions ( 5.3 )] Jaw Osteonecrosis [see Warnings and Precautions ( 5.4 )] Musculoskeletal Pain [see Warnings and Precautions ( 5.5 )] Atypical Fractures Including Femoral Fractures [see Warnings and Precautions ( 5.6 )] Renal Impairment [see Warnings and Precautions ( 5.7 )] Glucocorticoid-Induced Osteoporosis [see Warnings and Precautions ( 5.8 )] Laboratory Test Interactions [see Warnings and Precautions ( 5.9 )] Most common adverse reactions reported in greater than 10% of patients treated with risedronate and with a higher frequency than placebo are: back pain, arthralgia, abdominal pain, and dyspepsia ( 6.1 ) Hypersensitivity reactions (angioedema, generalized rash, bullous skin reactions, Stevens-Johnson syndrome, and toxic epidermal necrolysis), and eye inflammation (iritis, uveitis) have been reported rarely ( 6.2 ) To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: dddcd321-4d2e-4643-bf3c-7b752b33ba39. SPL document ID: 641c2a59-be2b-4246-8990-b7bf563012be. Label effective date: March 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Risedronate (FDA label)

Risedronate sodium is contraindicated in patients with the following conditions: Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia [see Warnings and Precautions ( 5.1 )] Inability to stand or sit upright for at least 30 minutes [see Dosage and Administration ( 2 ), Warnings and Precautions ( 5.1 )] Hypocalcemia [see Warnings and Precautions ( 5.2 )] Known hypersensitivity to risedronate sodium or any of its excipients. Angioedema, generalized rash, bullous skin reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported [see Adverse Reactions ( 6.2 )] Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia ( 4 , 5.1) Inability to stand or sit upright for at least 30 minutes ( 4 , 5.1) Hypocalcemia ( 4 , 5.3 ) Known hypersensitivity to any component of this product ( 4 , 6.2 )

Source: FDA prescribing information (DailyMed). Set ID: dddcd321-4d2e-4643-bf3c-7b752b33ba39. SPL document ID: 641c2a59-be2b-4246-8990-b7bf563012be. Label effective date: March 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Risedronate (FDA label)

Products Containing Same Active Ingredient: Patients receiving Atelvia should not be treated with risedronate sodium ( 5.1 ) Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue use if new or worsening symptoms occur ( 5.2 ) Hypocalcemia may worsen and must be corrected prior to use ( 5.3 ) Osteonecrosis of the Jaw has been reported ( 5.4 ) Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop ( 5.5 , 6.2 ) Atypical Fractures Including Femoral Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture.

Source: FDA prescribing information (DailyMed). Set ID: dddcd321-4d2e-4643-bf3c-7b752b33ba39. SPL document ID: 641c2a59-be2b-4246-8990-b7bf563012be. Label effective date: March 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Risedronate (FDA label)

No specific drug-drug interaction studies were performed. Risedronate is not metabolized and does not induce or inhibit hepatic microsomal drug-metabolizing enzymes (for example, Cytochrome P450). Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of risedronate ( 7.1 ) 7.1 Calcium Supplements/Antacids Co-administration of risedronate and calcium, antacids, or oral medications containing divalent cations will interfere with the absorption of risedronate. 7.2 Hormone Replacement Therapy One study of about 500 early postmenopausal women has been conducted to date in which treatment with risedronate sodium tablets 5 mg daily plus estrogen replacement therapy was compared to estrogen replacement therapy alone.

Source: FDA prescribing information (DailyMed). Set ID: dddcd321-4d2e-4643-bf3c-7b752b33ba39. SPL document ID: 641c2a59-be2b-4246-8990-b7bf563012be. Label effective date: March 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.